Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Priority Review Voucher Programs Poised For US Legislative Attention In 2020

Feb 18 2020

• By Sue Sutter

Priority Fast Lane Sign Airport First Class Luxury Notification Blue Light — US FDA seeks statutory clarity on biologics eligible for priority review vouchers. • Source: Shutterstock

Related Content

US FDA Priority Review Voucher Fee Continues Drop In FY 2020

Sep 30 2019

Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials

Feb 19 2019

Priority Review Vouchers Post Lower Average Approval Times Than Priority NMEs

Oct 16 2019

Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears

Dec 23 2016

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, FDA Says

Mar 03 2016

Additional Topics

United States Review Pathway Legislation Rare Diseases Pediatrics Regulation Infectious Diseases BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window